Addex Therapeutics SA, of Geneva, disclosed top-line data from a phase IIa study of ADX71149 in anxious depression, conducted by Janssen Research & Development LLC, of Raritan, N.J., part of Johnson & Johnson. Overall, ADX71149 was well tolerated and treatment emergent adverse events reported were similar to those seen in previous clinical studies.